Characterizing CAR T Cell Therapy Biomarkers Through Multianalyte Analysis

Identification and monitoring of biomarkers related to T cell activation and associated cytokine release syndrome (CRS) will be necessary to fully realize the immense potential of chimeric antigen receptor (CAR) T cell therapy. Such biomarkers could be used to guide clinical development of candidate therapies1, provide mechanistic insight into patterns of resistance2, and evaluate strategies to mitigate toxicity3. Establishment of predictive biomarkers is critical to maximizing therapeutic benefits of immunotherapy4. Correlating biomarkers with clinical evidence will facilitate early identification of patients at risk of developing CRS and enhance efforts to safely deliver CAR T therapy5.